A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe
and effective at decreasing the likelihood of a high-risk corneal graft rejection. Patients
who are "high-risk" for rejection have blood vessels growing from the white of the eye into
the cornea (clear, front region of the eye). The medication is used at the time of surgery
and in the weeks following surgery. Participants have a 50/50 chance at receiving the active
study medication or a placebo medication.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts Eye and Ear Infirmary Reza Dana, MD
Collaborators:
Bascom Palmer Eye Institute New York Presbyterian Hospital United States Department of Defense